Amgen
Amgen is a global independent biotechnology company headquartered in Thousand Oaks, California, that discovers, develops, manufactures, and commercializes biologic medicines across cardiovascular, oncology, inflammation, bone health, and rare disease therapeutic areas, serving millions of patients in approximately 100 countries worldwide.
- Company typePublic
- Founded1980
- HeadquartersThousand Oaks, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Amgen does
Amgen is one of the world's largest independent biotechnology companies, founded in 1980 and headquartered in Thousand Oaks, California. It discovers, develops, manufactures, and commercializes biologic medicines—therapeutic proteins produced using living cells—for serious illnesses across general medicine (cardiovascular, bone health, obesity), rare disease, inflammation, and oncology. Its platform combines human genetic data assets (via the deCODE Genetics acquisition), proprietary machine learning models (e.g., protein viscosity prediction from amino acid sequences), and generative biology approaches to drug discovery. Core commercial products include six franchises each exceeding $1 billion in annual revenue: Repatha (cardiovascular), Prolia/XGEVA (bone), Enbrel (inflammation), BLINCYTO and IMDELLTRA (oncology T-cell engagers), and Tezspire (severe asthma co-developed with AstraZeneca). The portfolio also includes a growing biosimilars franchise (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI) and rare disease assets (TAVNEOS, Tepezza, Krystexxa, Uplizna) acquired through the $27.8 billion Horizon Therapeutics acquisition.
Revenue is generated primarily through one-time sales of innovative biologic medicines through traditional pharmaceutical channels: direct sales forces targeting healthcare providers, contracts with hospital buying groups for institutional purchases, specialty pharmacy distribution for cold-chain biologics, and retail pharmacy wholesalers. Direct-to-patient programs (Amgen Now offering Repatha at $238/month for uninsured patients) provide a supplementary distribution and access layer. Manufacturing relies on a capital-intensive, multi-continent network spanning Thousand Oaks, Puerto Rico (the 1.7M sq ft flagship site), Rhode Island, Ohio (opened February 2024), Singapore, Ireland, and the Netherlands, with European headquarters in Zug, Switzerland and R&D centers in Cambridge, South San Francisco, Shanghai, and Hyderabad, India.
The business reaches millions of patients across approximately 100 countries. The pipeline includes 273 ongoing clinical trials and 30 Phase III programs, with MariTide (a GIPR/GLP-1R bispecific agonist for obesity) representing the most consequential late-stage asset targeted at a market where 90% of obesity remains untreated. Notable risks include regulatory scrutiny of TAVNEOS (FDA proposing withdrawal and EMA recommending revocation due to clinical trial data integrity issues inherited from ChemoCentryx), generic and biosimilar erosion of legacy franchises, and pricing pressure exemplified by Colorado's attempt to cap Enbrel at $31,200/year.
Amgen firmographics
Firmographics- Name
- Amgen
- Legal name
- Amgen Inc.
- Website
- https://amgen.com
- Company type
- Public
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Amgen is a global independent biotechnology company headquartered in Thousand Oaks, California, that discovers, develops, manufactures, and commercializes biologic medicines across cardiovascular, oncology, inflammation, bone health, and rare disease therapeutic areas, serving millions of patients in approximately 100 countries worldwide.
- Ownership category
- akta.pro rank
Amgen industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where Amgen is headquartered
LocationHeadquarters
- HQ city
- Thousand Oaks
- HQ country
- United States
- HQ region
- North America
Offices14 records
Markets served
Amgen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure, Personnel
Revenue model
- Specialty Pharmaceutical Sales: Amgen generates revenue primarily through the sale of innovative biologic medicines that treat serious illnesses. The company focuses on drugs for cardiovascular disease, rare diseases, inflammatory conditions, and cancer.
- Biosimilar Sales: Amgen commercializes biosimilar medicines including AMJEVITA (adalimumab-atto), MVASI (bevacizumab-awwb), KANJINTI (trastuzumab-anns), AVSOLA (infliximab-axxq), and RIABNI (rituximab-arrx) as biosimilars to reference products.
- Direct-to-Patient Programs: Amgen operates Amgen Now program offering Repatha at $238 per month for uninsured patients, demonstrating direct patient access programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Repatha patient assistance program pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Amgen product offering
Product offeringCore offering
Amgen discovers, develops, manufactures, and commercializes biologic medicines and small molecule therapies for serious illnesses across four therapeutic areas: cardiovascular/metabolic disease, bone health, inflammation, and oncology, with an expanded rare disease franchise following the Horizon Therapeutics acquisition. The company's portfolio includes innovative brands such as Repatha, Prolia, Enbrel, BLINCYTO, KYPROLIS, LUMAKRAS, IMDELLTRA, and Tezspire, alongside a growing biosimilars business (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI). Amgen also operates direct-to-patient access programs and pipeline candidates including the obesity therapy MariTide.
Product overview
Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines across four therapeutic areas: general medicine (cardiovascular, obesity, bone health), rare disease, inflammation, and oncology. The company operates a diversified portfolio of core products including biologic medicines (EPOGEN, NEUPOGEN, Enbrel, Prolia, XGEVA, Repatha), oncology treatments (BLINCYTO, KYPROLIS, LUMAKRAS, IMDELLTRA), inflammation therapies (Tezspire, Otezla), and rare disease medicines (TAVNEOS, UPLIZNA, TEPEZZA). Following acquisitions of Horizon Therapeutics (2023) and ChemoCentryx (2022), Amgen expanded into rare diseases with TEPEZZA for thyroid eye disease and Krystexxa for gout. The company also maintains a growing biosimilars business (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI). The pipeline includes MariTide for obesity. Amgen operates across approximately 100 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- IMDELLTRA (tarlatamab): T-cell engager therapy for extensive-stage small cell lung cancer (ES-SCLC), approved by FDA in May 2024 and by European Commission in June 2026.
- IMDYLLTRA (tarlatamab)
- Repatha (evolocumab)
- Enbrel (etanercept)
- Prolia (denosumab)
- TEZSPIRE (tezepelumab)
- UPLIZNA (inebilizumab)
- TAVNEOS (avacopan)
- Tepezza (teprotumumab)
- Krystexxa (pegloticase)
- MariTide
- BLINCYTO (blinatumomab)
- LUMAKRAS (sotorasib)
- Kyprolis (carfilzomib)
- Nplate (romiplostim)
- Corlanor (ivabradine)
- Sensipar/Mimpara (cinacalcet)
- EVENITY (romosozumab)
- Parsabiv (etelcalcetide)
- Vectibix (panitumumab)
- Aranesp (darbepoetin alfa)
- Neulasta (pegfilgrastim)
- EPOGEN (epoetin alfa)
- NEUPOGEN (filgrastim)
- IMJUDIA / AMJEVITA
- Biosimilars portfolio
- LabXchange
- Amgen Scholars
- Breakaway from Cancer
Products and services
- EPOGEN (epoetin alfa)
- NEUPOGEN (filgrastim)
- Neulasta (pegfilgrastim)
- Enbrel (etanercept)
- Repatha (evolocumab)
- Prolia (denosumab)
- XGEVA (denosumab)
- EVENITY (romosozumab)
- Tezspire (tezepelumab)
- Otezla (apremilast)
- BLINCYTO (blinatumomab)
- KYPROLIS (carfilzomib)
- LUMAKRAS (sotorasib)
- IMDELLTRA (tarlatamab-dlle)
- Vectibix (panitumumab)
- Nplate (romiplostim)
- Corlanor (ivabradine)
- Sensipar/Parsabiv (cinacalcet/etelcalcetide)
- Aimovig (erenumab)
- TEPEZZA (teprotumumab)
- Krystexxa (pegloticase)
- TAVNEOS (avacopan)
- UPLIZNA (inebilizumab)
- AMJEVITA (adalimumab-atto)
- MVASI (bevacizumab-awwb)
- KANJINTI (trastuzumab-anns)
- AVSOLA (infliximab-axxq)
- RIABNI (rituximab-arrx)
- MariTide (maridebart cafraglutide)
- Amgen Now Patient Assistance Program
Quantifiable outcome
- Repatha reduced risk of major cardiovascular events by 29% in high-risk diabetes patients
- +2 more outcomes
Companies that use Amgen
Customer profileNamed customers2 records
Segments6 records
Ideal customer profiles2 records
Amgen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Amgen partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, minor and regional.
- OpenAIcoreAmgen is partnering with OpenAI as part of GPT-Rosalind launch for life sciences research, applying AI models across scientific workflows.
- AstraZenecacoreAstraZeneca and Amgen are currently piloting FDA's real-time clinical trial monitoring approach, streaming live clinical data into FDA review systems.
- FDAcoreAmgen is piloting FDA's real-time clinical trial monitoring program, streaming live clinical data directly into FDA review systems through an AI-powered cloud platform.
- FIFA World Cup 2026minorOfficial biotech partner of Los Angeles Host Committee for FIFA World Cup 2026, reaching global audience of 6 billion people.
- Amgen India - HyderabadminorTechnology and innovation center in Hyderabad expanding digital, data science, and AI capabilities as part of global technology operations.
- Kissei PharmaceuticalregionalDistribution partner for Tavneos in Japan. Has reported 20 deaths among Japanese patients on the drug.
- AstraZenecacoreCo-development and co-commercialization of Tezspire (tezepelumab) for severe asthma. AstraZeneca provides global commercialization capabilities while Amgen leads manufacturing.
- CSL ViforcoreCSL commercializes TAVNEOS outside the U.S. under collaboration with Vifor Fresenius Medical Care Renal Pharma. European rights held by CSL's Vifor.
- BeiGenecoreStrategic collaboration to expand Amgen's oncology presence in China. BeiGene provides local market expertise and commercial infrastructure for Amgen's oncology portfolio in China.
- Amgen-Betta Pharmaceuticals Joint VentureregionalJoint venture established in China for commercialization of Amgen medicines in the Chinese market.
- Amgen Astellas BioPharma K.K.regionalAlliance in Japan for development and commercialization of medicines. Became wholly-owned affiliate in 2020, renamed Amgen K.K.
- ServierminorCollaboration obtaining U.S. commercial rights to ivabradine for cardiovascular treatments.
Scale indicators13 records
Recent moves10 records
Expansion highlights7 records
Amgen competitors and assessment
Company assessmentDirect peers
- Eli Lilly: Eli Lilly is a major global biopharmaceutical company with overlapping therapeutic areas including cardiometabolic, oncology, immunology, and rare disease. Lilly is the most direct competitor in obesity via Mounjaro/Zepbound, where Amgen is positioning MariTide. Both companies operate large-scale biologic manufacturing and pursue AI-driven R&D.
- Regeneron Pharmaceuticals: Regeneron is a science-driven biotech with a biologic-heavy portfolio including Eylea, Dupixent (with Sanofi), and Libtayo. Highly comparable to Amgen in monoclonal antibody expertise, biotech origin, and innovation pipeline, with overlap in ophthalmology/rare disease versus Amgen's TEPEZZA and inflammation franchises.
- Vertex Pharmaceuticals: Vertex is a global biotechnology company specializing in serious diseases with a focus on small-molecule and biologic therapies for cystic fibrosis, pain, and rare diseases. Comparable to Amgen as a similarly scaled, R&D-intensive biotech, particularly relevant given Amgen's rare disease expansion via Horizon (CF overlap in CFTR-modulator-adjacent diseases).
- Biogen: Biogen is a biotechnology company focused on serious neurological, autoimmune, and rare diseases with a biologic-heavy portfolio. Comparable to Amgen in biotech origin, biologic manufacturing capability, and rare-disease strategic focus, particularly relevant given Amgen's UPLIZNA (NMOSD/IgG4 disease) and TAVNEOS (vasculitis) franchises.
Broad incumbents
- Pfizer: Pfizer is one of the largest global biopharmaceutical companies with a similarly diversified portfolio spanning oncology, inflammation, vaccines, and rare disease. Pfizer's broad specialty/biologic pipeline and global commercial footprint make it a direct comparison point for Amgen's diversified specialty pharma model and post-Horizon scale.
- Merck & Co. Merck operates a large R&D-driven pharmaceutical business with deep oncology, vaccines, and specialty portfolios. Comparable to Amgen in scale, biologics capability, and global commercial reach, particularly in oncology where both compete (Amgen's LUMAKRAS, IMDELLTRA versus Merck's Keytruda).
- Bristol Myers Squibb: Bristol Myers Squibb is a diversified specialty biopharma with a large oncology and immunology portfolio. Comparable to Amgen in biologics focus, oncology pipeline depth (BLINCYTO/IMDELLTRA versus BMS hematology assets), and the post-LOE diversification strategy Amgen is pursuing with Horizon.
- AbbVie: AbbVie is a global biopharmaceutical company with major franchises in immunology, oncology, and neuroscience. Highly comparable to Amgen in biologics-heavy portfolio mix, large-acquisition growth strategy (Humira heritage, Allergan integration), and biosimilar exposure as Humira faces AMJEVITA and other biosimilars including Amgen's.
- Johnson & Johnson Innovative Medicine: J&J Innovative Medicine is a diversified biopharma with deep immunology, oncology, and pulmonary hypertension franchises. Comparable to Amgen in scale, R&D intensity, and global commercial reach; J&J's Stelara/Tremfya overlap with Enbrel/Tezspire in immunology, while its oncology pipeline overlaps Amgen's.
- Gilead Sciences: Gilead is a biopharmaceutical company with a diversified specialty portfolio in HIV, oncology, and inflammation. Comparable to Amgen in scale and biologics orientation, with overlap in inflammation/immunology (Gilead's post-Celgene assets) and oncology (BLINCYTO/IMDELLTRA versus Gilead's Trodelvy).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Amgen social profiles
Digital presenceAmgen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amgen leadership team
Management profileNumber of profiles
Profiles14 records
Amgen subsidiaries and ownership
Company hierarchySubsidiaries13 records
Amgen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amgen M&A and investment
M&A and investmentM&A27 records
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amgen
What does Amgen do?
Amgen discovers, develops, manufactures, and commercializes biologic medicines and small molecule therapies for serious illnesses across four therapeutic areas: cardiovascular/metabolic disease, bone health, inflammation, and oncology, with an expanded rare disease franchise following the Horizon Therapeutics acquisition. The company's portfolio includes innovative brands such as Repatha, Prolia, Enbrel, BLINCYTO, KYPROLIS, LUMAKRAS, IMDELLTRA, and Tezspire, alongside a growing biosimilars business (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI). Amgen also operates direct-to-patient access programs and pipeline candidates including the obesity therapy MariTide.
Is Amgen a public or private company?
Amgen is a public company. It is classified as public and is currently operating.
When was Amgen founded?
Amgen was founded in 1980. It employs 5,001 to 10,000 people.
Where is Amgen based?
Amgen is headquartered in Thousand Oaks, United States, in the North America region.
How does Amgen make money?
Three revenue lines are on record. Specialty Pharmaceutical Sales are the primary driver. The others are biosimilar Sales and direct-to-Patient Programs.
Who are Amgen's main competitors?
Direct peers on record are Eli Lilly, Regeneron Pharmaceuticals, Vertex Pharmaceuticals and Biogen. Broad incumbents are Pfizer, Merck & Co., Bristol Myers Squibb, AbbVie, Johnson & Johnson Innovative Medicine and Gilead Sciences.
Does Amgen have an API?
No public API is recorded for Amgen.
What industry is Amgen in?
Amgen's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325414 and its SIC code is 2836.